Endocrine resistance in breast cancer: From cellular signaling pathways to epigenetic mechanisms

Transcription

Volumn 3, Issue 4, 2012, Pages

  Bianco, Stéphanie ^a   Gévry, Nicolas ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Breast cancer; Chromatin; Endocrine resistance; Epigenetic; Genomic; Transcription factor

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; G PROTEIN COUPLED RECEPTOR 30; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TAMOXIFEN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR PBX1; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CANCER RESISTANCE; DNA METHYLATION; DRUG DEGRADATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; ENZYME ACTIVITY; EPIGENETICS; ERALPHA GENE; ESTROGEN ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; GENE; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; PHARMACOGENOMICS; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; BREAST TUMOR; CHROMATIN; DRUG RESISTANCE; FEMALE; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHROMATIN; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSCRIPTION, GENETIC;

EID: 85046982181     PISSN: 21541264     EISSN: 21541272     Source Type: Journal    
DOI: 10.4161/trns.20496     Document Type: Review

References (45)

1. Badve S, Nakshatri H. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol 2009; 62:6-12; PMID:18794199; http://dx.doi.org/10.1136/jcp.2008.059899.
2. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011; 11:597-608; PMID:21779010; http://dx.doi.org/10.1038/nrc3093.
3. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, et al.; NCI-Naple Breast Cancer Group. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005; 12:721-47; PMID:16322319; http://dx.doi.org/10.1677/erc.1.00857.
4. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9:631-43; PMID:19701242; http://dx.doi.org/10.1038/nrc2713.
5. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011; 62:233-47; PMID:20887199; http://dx.doi.org/10.1146/annurev-med-070909-182917.
6. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Lett 2007; 256:1-24; PMID:17475399; http://dx.doi.org/10.1016/j.canlet.2007.03.016.
7. Singh MS, Francis PA, Michael M. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast 2011; 20:111-8; PMID:21185724; http://dx.doi.org/10.1016/j.breast.2010.11.003.
8. Barone I, Brusco L, Fuqua SA. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 2010; 16:2702-8; PMID:20427689; http://dx.doi.org/10.1158/1078-0432.CCR-09-1753.
9. Rao J, Jiang X, Wang Y, Chen B. Advances in the understanding of the structure and function of ER-α36, a novel variant of human estrogen receptoralpha. J Steroid Biochem Mol Biol 2011; 127:231-7; PMID:21888973; http://dx.doi.org/10.1016/j.jsbmb.2011.08.004.
10. de Leeuw R, Neefjes J, Michalides R. A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer 2011; 2011:232435; PMID:22295213; http://dx.doi.org/10.4061/2011/232435.
11. Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir JM, Corbo L. Cracking the estrogen receptor's posttranslational code in breast tumors. Endocr Rev 2011; 32:597-622; PMID:21680538; http://dx.doi.org/10.1210/er.2010-0016.
12. Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J, et al. Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol 2009; 217:372-9; PMID:18991335; http://dx.doi.org/10.1002/path.2455.
13. Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van't Veer LJ, et al. PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 2011; 125:1-12; PMID:20213082; http://dx.doi.org/10.1007/s10549-010-0798-y.
14. Zwart W, Griekspoor A, Berno V, Lakeman K, Jalink K, Mancini M, et al. PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. EMBO J 2007; 26:3534-44; PMID:17627277; http://dx.doi.org/10.1038/sj.emboj.7601791.
15. Carascossa S, Dudek P, Cenni B, Briand PA, Picard D. CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptoralpha by cAMP. Genes Dev 2010; 24:708-19; PMID:20360387; http://dx.doi.org/10.1101/gad.568410.
16. Eccles SA. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 2011; 55:685-96; PMID:22161825; http://dx.doi.org/10.1387/ijdb.113396se.
17. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol-3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011; 29:4452-61; PMID:22010023; http://dx.doi.org/10.1200/JCO.2010.34.4879.
18. Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat 2011; 128:457-66; PMID:21607586; http://dx.doi.org/10.1007/s10549-011-1584-1.
19. Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat 2010; 123:87-96; PMID:19911269; http://dx.doi.org/10.1007/s10549-009-0624-6.
20. Nagalingam A, Tighiouart M, Ryden L, Joseph L, Landberg G, Saxena NK, et al. Med1 plays a critical role in the development of tamoxifen resistance. Carcinogenesis 2012; 33:918-30; PMID:22345290; http://dx.doi.org/10.1093/carcin/bgs105.
21. Zhao W, Zhang Q, Kang X, Jin S, Lou C. AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells. Biochem Biophys Res Commun 2009; 380:699-704; PMID:19285025; http://dx.doi.org/10.1016/j.bbrc.2009.01.155.
22. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008; 456:663-6; PMID:19005469; http://dx.doi.org/10.1038/nature07483.
23. Caldon CE, Sutherland RL, Musgrove E. Cell cycle proteins in epithelial cell differentiation: implications for breast cancer. Cell Cycle 2010; 9:1918-28; PMID:20473028; http://dx.doi.org/10.4161/cc.9.10.11474.
24. Andorfer CA, Necela BM, Thompson EA, Perez EA. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med 2011; 17:313-9; PMID:21376668; http://dx.doi.org/10.1016/j.molmed.2011.01.006.
25. Fu SW, Chen L, Man YG. miRNA Biomarkers in Breast Cancer Detection and Management. J Cancer 2011; 2:116-22; PMID:21479130; http://dx.doi.org/10.7150/jca.2.116.
26. Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011; 30:1082-97; PMID:21057537; http://dx.doi.org/10.1038/onc.2010.487.
27. Zhao Y, Deng C, Lu W, Xiao J, Ma D, Guo M, et al. let-7 MicroRNAs Induce Tamoxifen Sensitivity by Downregulation of Estrogen Receptor α Signaling in Breast Cancer. Mol Med 2011; 17:1233-41; PMID:21826373; http://dx.doi.org/10.2119/molmed.2010.00225.
28. Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE. Oncogenic HER2Delta16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 2010; 31:2049-57; PMID:20876285; http://dx.doi.org/10.1093/carcin/bgq192.
29. Kip1. J Biol Chem 2008; 283:29897-903; PMID:18708351; http://dx.doi.org/10.1074/jbc.M804612200.
30. Sachdeva M, Wu H, Ru P, Hwang L, Trieu V, Mo YY. MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene 2011; 30:822-31; PMID:20956939; http://dx.doi.org/10.1038/onc.2010.463.
31. Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, et al. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res 2011; 71:2926-37; PMID:21393507; http://dx.doi.org/10.1158/0008-5472.CAN-10-3369.
32. Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, Bénès V, et al. Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res 2009; 69:8332-40; PMID:19826037; http://dx.doi.org/10.1158/0008-5472.CAN-09-2206.
33. Gévry N, Hardy S, Jacques PE, Laflamme L, Svotelis A, Robert F, et al. Histone H2A. Z is essential for estrogen receptor signaling. Genes Dev 2009; 23:1522-33; PMID:19515975; http://dx.doi.org/10.1101/gad.1787109.
34. Svotelis A, Gévry N, Gaudreau L. Regulation of gene expression and cellular proliferation by histone H2A.Z. Biochem Cell Biol 2009; 87:179-88; PMID:19234533; http://dx.doi.org/10.1139/O08-138.
35. Svotelis A, Gévry N, Grondin G, Gaudreau L. H2A. Z overexpression promotes cellular proliferation of breast cancer cells. Cell Cycle 2010; 9:364-70; PMID:20023423; http://dx.doi.org/10.4161/cc.9.2.10465.
36. Svotelis A, Bianco S, Madore J, Huppé G, Nordell-Markovits A, Mes-Masson AM, et al. H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERα ligand dependency. EMBO J 2011; 30:3947-61; PMID:21841772; http://dx.doi.org/10.1038/emboj.2011.284.
37. Magnani L, Eeckhoute J, Lupien M. Pioneer factors: directing transcriptional regulators within the chromatin environment. Trends Genet 2011; 27:465-74; PMID:21885149; http://dx.doi.org/10.1016/j.tig.2011.07.002.
38. Zaret KS, Carroll JS. Pioneer transcription factors: establishing competence for gene expression. Genes Dev 2011; 25:2227-41; PMID:22056668; http://dx.doi.org/10.1101/gad.176826.111.
39. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011; 43:27-33; PMID:21151129; http://dx.doi.org/10.1038/ng.730.
40. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012; 481:389-93; PMID:22217937.
41. Magnani L, Ballantyne EB, Zhang X, Lupien M. PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer. PLoS Genet 2011; 7:1002368; PMID:22125492; http://dx.doi.org/10.1371/journal.pgen.1002368.
42. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66:11954-66; PMID:17178894; http://dx.doi.org/10.1158/0008-5472.CAN-06-1666.
43. Phuong NT, Kim SK, Lim SC, Kim HS, Kim TH, Lee KY, et al. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat 2011; 130:73-83; PMID:21170675; http://dx.doi.org/10.1007/s10549-010-1304-2.
44. Vesuna F, Lisok A, Kimble B, Domek J, Kato Y, van der Groep P, et al. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptorα. Oncogene 2011; PMID:22056872; http://dx.doi.org/10.1038/onc.2011.483.
45. Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, et al. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev 2010; 24:2219-27; PMID:20889718; http://dx.doi.org/10.1101/gad.1944810.